Category Archives: MS Treatment

Most Effective Ms Treatment by NoMoreVitamins com Health Insurance might make pills cheaper, but this helps you take LESS pills! Are you ready to feel less pain, less inflammation and even balance your blood sugar? Oh, and take less pills?... By: stacy robins … Continue reading →

How Does Tecfidera Compare With Other MS Drugs? By Kathleen Doheny WebMD Health News Reviewed by Brunilda Nazario, MD April 25, 2013 -- With the arrival of Tecfidera this spring, people with multiple sclerosis now have three oral drugs to choose from to treat the relapsing form of the disease. Tecfidera (dimethyl fumarate) joins two other oral MS drugs. Aubagio (teriflunomide) was approved in 2012, and Gilenya (fingolimod) was approved in 2010. For the 350,000 people in the U.S. who have MS, these drugs represent a treatment breakthrough. Other MS drugs used to treat the relapsing form are injected or given through an IV. All three oral MS drugs are expensive. Tecfidera's wholesale cost is nearly $55,000 a year. Gilenya and Aubagio cost $60,000 and $45,000 a year. All three drugs also have side effects. The active ingredient in Tecfidera has been linked to four cases of a rare but sometimes fatal brain disease, progressive multifocal leukoencephalopathy (PML). That side effect was not seen in patients taking Tecfidera during clinical trials, the company making the MS drug says. With three similar drugs, what do patients need to know? For answers, WebMD turned to Barbara Giesser, MD, professor of neurology and … Continue reading →

Latest Treatment For Ms by NoMoreVitamins com http://NoMoreVitamins.com - Don't let yourself take pain pills for the rest of your life, please! There's another way no one has told you about, the holistic... By: steve matthews … Continue reading →

Acorda Therapeutics, Inc. ( ACOR ) and Mayo Clinic announced the enrollment of the first patient in a phase I safety study of rHIgM22. rHIgM22, a remyelinating monoclonal antibody, is being evaluated for the treatment of multiple sclerosis (MS). The study will evaluate the safety, tolerability and efficacy of rHIgM22. Acorda already has a presence in the MS market in the form of Ampyra, which is approved for the improvement of walking in patients suffering from MS. Acorda is currently working on expanding Amypra's label into additional indications. The company recently presented encouraging data on Ampyra from two phase II proof-of-concept studies for cerebral palsy and post-stroke deficit. The company plans to discuss further development of Ampyra for the post-stroke deficit indication with the FDA. Acorda has an agreement with Biogen Idec Inc. ( BIIB ) for marketing Ampyra outside the US under the trade name Fampyra. Fampyra is approved in the EU, Canada, Australia, Israel and New Zealand. According to Acorda, about 400,000 people in the US suffer from MS. In addition, every year approximately 10,000 patients are diagnosed. Moreover, in the EU, approximately 600,000 people have MS. We remind investors that companies like Biogen and Novartis AG ( … Continue reading →

Emily Munoz spends much of her time doing fundraising events and spreading awareness about multiple sclerosis, a chronic disease that hasnt broken her spirit and positivity since she was diagnosed in 2006. Munoz, 32, of Ozone Park, will be preparing to join her Just Es-Support team in the seventh New York Multiple Sclerosis Walk at South Street Seaport on Sunday, April 28. According to Munoz, when she was diagnosed with MS at the age of 26, she didnt understand what the condition was or why it happened to her. I felt confused. As a young lady I wasnt really sure what MS was until my neurologist told me that talk show host Montel Williams had it as well, said Munoz. But after a while I had a better outlook on things, and had a positive attitude about it. I wasnt going to let it stop me from doing anything Ive been already doing. The chronic illness, which affects the central nervous system, caused Munoz to have spasms and pain attacks every three months, until one day she experienced numbness on the entire right side of her body. Scared and nervous about her condition, she was afraid to be in public … Continue reading →

Acorda Therapeutics, Inc. (ACOR) and Mayo Clinic announced the enrollment of the first patient in a phase I safety study of rHIgM22. rHIgM22, a remyelinating monoclonal antibody, is being evaluated for the treatment of multiple sclerosis (MS). The study will evaluate the safety, tolerability and efficacy of rHIgM22. Acorda already has a presence in the MS market in the form of Ampyra, which is approved for the improvement of walking in patients suffering from MS. Acorda is currently working on expanding Amypras label into additional indications. The company recently presented encouraging data on Ampyra from two phase II proof-of-concept studies for cerebral palsy and post-stroke deficit. The company plans to discuss further development of Ampyra for the post-stroke deficit indication with the FDA. Acorda has an agreement with Biogen Idec Inc. (BIIB) for marketing Ampyra outside the US under the trade name Fampyra. Fampyra is approved in the EU, Canada, Australia, Israel and New Zealand. According to Acorda, about 400,000 people in the US suffer from MS. In addition, every year approximately 10,000 patients are diagnosed. Moreover, in the EU, approximately 600,000 people have MS. We remind investors that companies like Biogen and Novartis AG (NVS) have a strong presence … Continue reading →

The Forgan Smith building at the UQ St Lucia campus will be lit up red in support of MS Awareness Month. The middle section of the northern side of the building will be floodlit from 6pm to 11pm every night for the duration of MS Awareness Month, as part of the effort to raise awareness of the debilitating disease. Multiple Sclerosis attacks the brain and spinal cord, causing irreparable damage. It is the most common acquired chronic neurological condition among young Australian adults. Researchers at the UQ Centre for Clinical Research (UQCCR), the School of Medicine, and the Queensland Brain Institute (QBI) are working to find treatments to help the 23,000 Australians living with the disease. UQ MS expert Dr Judith Greer said the UQCCR was working on five main MS projects. My current work focuses on the role of molecules called antibodies, she said. There is a lot of suggestive evidence that these antibodies might cause a faster progression of disease in people with multiple sclerosis, but this remains to be proven. We're investigating the mechanisms by which antibodies that target the most abundant protein in myelin (called proteolipid protein or PLP) could hasten MS disease progression, Dr Greer … Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today positive top-line results from the TOPIC trial for AUBAGIO (teriflunomide). The trial was designed to assess whether early initiation of AUBAGIO (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS). Clinically isolated syndrome (CIS) is defined as a first clinical attack with features suggestive of MS. It typically occurs in young adults and is often a prelude to CDMS. In the TOPIC trial, patients receiving AUBAGIO 14 mg and 7 mg were significantly less likely to develop CDMS, defined as occurrence of a second clinical attack, the primary endpoint, as compared to placebo. Additional results, including key secondary and tertiary objectives, will be presented at a forthcoming scientific meeting. Primary results were: Clinically Isolated Syndrome (CIS) is often a prelude to clinically definite multiple sclerosis, and early treatment has proved beneficial, said Dr. Aaron E. Miller, Medical Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center. These findings are important as there is an unmet need for an efficacious oral option for patients at this … Continue reading →

By Brenda Goodman HealthDay Reporter WEDNESDAY, April 24 (HealthDay News) -- The active ingredient in a drug that's expected to become a popular treatment for multiple sclerosis has been linked to four European cases of a rare but sometimes fatal brain disease called progressive multifocal leukoencephalopathy (PML). The ingredient, dimethyl fumarate, is used in a drug called Fumaderm that was approved in Germany in 1994 to treat the skin condition psoriasis. It is also in a different but closely related medication called Tecfidera, which was just approved by the U.S. Food and Drug Administration in March for the treatment of multiple sclerosis (MS). It is known as a fumaric acid ester, which is commonly used as a food additive and has been used to treat psoriasis in Germany for 30 years. According to reports published in the April 25 issue of the New England Journal of Medicine, however, four patients who were taking Fumaderm to treat their psoriasis developed PML. In a letter responding to the reports, Biogen, the company that makes both drugs, said Tecfidera may be safer because it contains only dimethyl fumarate, while Fumaderm also contains three other fumaric acid esters. The company also noted that none … Continue reading →

Why did Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) rise 2% on Wall Street yesterday? At first, it seemed that the reason was Teva's announcement of the formation of a Global Specialty Medicines group, but it turns out that problems at rival Biogen were the more likely cause. Bloomberg reported yesterday that a Biogen psoriasis treatment called Fumaderm was linked to three fatal cases of a brain infection known as progressive multifocal leukoencephalopathy, or PML. Fumaderm is an earlier version of Tecfidera, Biogen's orally administered treatment for multiple sclerosis that competes with Teva's flagship product Copaxone, which is administered by injection. Tecfidera (or BG-12 as it was formerly known) was approved by the US Food and Drug Administration for sale in the US less than a month ago. Analysts expect it to have sales in the billions of dollars in the coming years and to become the highest selling multiple sclerosis treatment. Copaxone currently has 40% of the market. Biogen's share price fell 3% yesterday. Bloomberg quoted researchers from VU University Medical Center in Amsterdam as saying that the risk deserved attention since other medicines with the same active ingredients are emerging and may be used to treat a … Continue reading →